Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY crawled date : 2021 - 08 - 16 save search
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study
Published: 2021-08-16 (Crawled : 13:00) - biospace.com/
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
therapy phase 3
Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Published: 2021-08-16 (Crawled : 00:00) - prnewswire.com
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
INCY | $53.725 0.55% 630K
|
Health Technology
|
| O: 0.53%
H: 0.72%
C: 0.68%
treatment therapy phase 3
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.